A Study of Bimagrumab in Participants With HFpEF

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 540 participants.

Also called NCT07920887

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 540 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07920887
  • EU CT 2026-527983-34-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Hungary, Italy, Poland (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07920887. Randomized; double masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Bimagrumab in Participants With HFpEF
Acronym
ACTIVATE-HFpEF
Condition
Heart Failure, Diastolic
Condition
Diastolic Heart Failure
Condition
Heart Failure, Normal Ejection Fraction
Condition
Heart Failure, Preserved Ejection Fraction
Intervention (Drug)
Bimagrumab
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07920887
Content hash
3f7a83be3dd651aecaf6e4520d692a31e28d51a2b5e11b7d5f6691ad834a5670